利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.01 秒)

    LPS-Containing analgesics and veterinary analgesics
    5.
    发明公开
    LPS-Containing analgesics and veterinary analgesics 失效
    含LPS的肠化学和兽医学

    公开(公告)号：EP0472467A3

    公开(公告)日：1993-03-17

    申请号：EP91402276.9

    申请日：1991-08-20

    申请人： CHIBA FLOUR MILLING CO. LTD. ,  Soma, Gen-Ichiro ,  Mizuno, Den'Ichi

    发明人： Soma, Gen-Ichiro ,  Yoshimura, Kiyoshi ,  Tsukioka, Daisuke ,  Mizuno, Den'Ichi ,  Oshima, Haruyuki Tategaoka-Danchi 2-10-513

    IPC分类号： A61K37/20

    CPC分类号： C12R1/425 ,  A61K35/74 ,  A61K45/05 ,  C12P19/04 ,  C12R1/01 ,  Y02A50/475 ,  Y10S514/885

    摘要： An analgesic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and
       a method of treating pain of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the pain of said animal.

    Novel long-chain glycolipid structure
    6.
    发明公开
    Novel long-chain glycolipid structure 失效
    新型长链糖脂结构

    公开(公告)号：EP0344955A2

    公开(公告)日：1989-12-06

    申请号：EP89305153.2

    申请日：1989-05-22

    申请人： The Biomembrane Institute

    发明人： Nudelman, Edward D., The Biomenbrane Institute ,  Levery, Steven B., The Biomenbrane Institute ,  Stroud, Mark R., The Biomenbrane Institute ,  Salyan, Mary Ellen K., The Biomenbrane Institute ,  Hakomori, Sen-itiroh, The Biomenbrane Institute

    IPC分类号： C07H15/00 ,  C08B37/00 ,  A61K39/00 ,  A61K37/20 ,  C12P21/00 ,  A61K39/395

    CPC分类号： C07H15/10 ,  A61K38/00 ,  A61K39/00 ,  C07K16/30 ,  G01N33/66 ,  G01N33/92

    摘要： A substantially pure compound comprising an unbranched ceramide polysaccharide type 2 chain having the following structure: wherein Gal represents galactose, GlcNAc represents N -acetylglucoseamine, Fuc represents fucose and Cer represents ceramide. A substantially pure compound comprising an unbranched ceramide polysaccharide type 2 chain having the following structure: wherein Gal represents galactose, GlcNAc represents N -acetylglucoseamine, Fuc represents fucose, Cer represents ceramide and NeuAc represents sialic acid. Antibodies that are specific to portions of the above-described compounds, wherein the portions comprise the internal α1->3 fucosyl residue and/or the terminal sialic acid residue. Immunogens for producing antibodies to the above-described compounds or portions thereof. A method of actively immunizing against tumors that express the above-described compounds.

    摘要翻译： 包含具有以下结构的非支链神经酰胺多糖2型链的基本上纯的化合物：其中Gal代表半乳糖，GlcNAc代表N-乙酰葡萄糖胺，Fuc代表岩藻糖并且Cer代表神经酰胺。 包含具有以下结构的非支链神经酰胺多糖2型链的基本上纯的化合物：其中Gal代表半乳糖，GlcNAc代表N-乙酰葡萄糖胺，Fuc代表岩藻糖，Cer代表神经酰胺，NeuAc代表唾液酸。 特异于上述化合物部分的抗体，其中所述部分包含内部α1→3岩藻糖基残基和/或末端唾液酸残基。 用于产生针对上述化合物或其部分的抗体的免疫原。 主动免疫抵抗表达上述化合物的肿瘤的方法。

    Blood-treating material
    7.
    发明公开
    Blood-treating material 失效
    Mittel zur Blutbehandlung。

    公开(公告)号：EP0107119A1

    公开(公告)日：1984-05-02

    申请号：EP83109905.6

    申请日：1983-10-04

    申请人： TORAY INDUSTRIES, INC.

    发明人： Kodama, Masashi ,  Katayama, Yutaka ,  Tani, Toru ,  Teramoto, Kazuo ,  Murakami, Matsuo

    IPC分类号： A61K47/00 ,  A61K37/20 ,  A61M1/36

    CPC分类号： A61K35/74 ,  A61K31/715 ,  G01N2400/50

    摘要： The present invention provides (1) a blood-treating material comprising a lipopolysaccharide derived from cell walls of Gram-negative bacteria and immobilized by an insoluble carrier containing an amino group or a carboxyl group and (2) a process for producing the blood-treating material characterized by reacting a condensing agent with a mixture of the lipopolysaccharide and the insoluble carrier.
    Lipopolysaccharides have been known to have antitumor effects against malignant tumors. However, they could not be used safely, since their fatal doses are very close to the minimum effective doses in the treatment of the tumors.
    The present invention makes it possible to reduce the lethal toxicity of the above-mentioned lipopolysaccharides and provide a new blood-treating material that can be used safely for therapy of cancer, because this blood-treating material has antitumor effects similar to those of the lipopolysaccharides derived from cell walls of Gram-negative bacteria but no fatal effects.

    摘要翻译： 本发明提供（1）一种血液处理材料，其特征在于，含有衍生自革兰氏阴性细菌的细胞壁的脂多糖并通过含有氨基或羧基的不溶性载体固定的血液处理材料和（2） 其特征在于使缩合剂与脂多糖和不溶性载体的混合物反应。 已知脂多糖对恶性肿瘤具有抗肿瘤作用。 然而，它们不能安全使用，因为它们的致命剂量非常接近治疗肿瘤的最小有效剂量。 本发明使得可以降低上述脂多糖的致死毒性，并提供可以安全地用于癌症治疗的新型血液处理材料，因为该血液处理材料具有与脂多糖类似的抗肿瘤效果 衍生自革兰氏阴性细菌的细胞壁，但没有致命的影响。

    TOCOPHEROL-BASED PHARMACEUTICAL SYSTEMS
    10.
    发明授权
    TOCOPHEROL-BASED PHARMACEUTICAL SYSTEMS 失效
    基于TOCOPHEROL的药物系统

    公开(公告)号：EP0382779B1

    公开(公告)日：1993-08-11

    申请号：EP88909942.0

    申请日：1988-10-19

    申请人： THE LIPOSOME COMPANY, INC.

    发明人： JANOFF, Andrew, S. ,  BONI, Lawrence ,  BOLCSAK, Lois, E. ,  MINCHEY, Sharma, R. ,  WEISS, Steven, J.

    IPC分类号： A61K37/20 ,  A61K37/22

    CPC分类号： A61K31/415 ,  A61K9/1272

    摘要： A method for making a pharmaceutical composition is described. The composition is comprised of an organic acid derivative of alpha tocopherol, and may additionally comprise other lipids. The composition may be in the form of liposomes, and as such are associated with or entrap a bioactive agent. Particularly suited for such systems are drugs stable at acidic pH, for example drugs having imidazole groups, such as pilocarpine. The composition requires a stabilizer to maintain the bilayer phase of the organic acid derivative of alpha tocopherol in a low pH environment. Such a stabilizer is for example a detergent. Upon in vivo administration of the system and concomitant increase of pH, viscosity of the preparation increases.